DMCC Speciality Chemicals Ltd Q4 FY21 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Objective to double revenue once new projects come up, potentially reaching around Rs. 400 crore turnover by FY24.
- Sulfuric acid plant at Dahej expected to run at full capacity soon, contributing significantly to revenue.
- Specialty chemical products have good visibility with customers eagerly waiting for capacity expansion.
- Multipurpose specialty plants will take time to ramp up, with some products scaling faster than others.
- Specialty chemical segment targets EBITDA margins above 30% for new products.
- Bulk chemicals expected to start first, with commodity chemicals having lower margins initially, followed by stabilization.
- Long-term strategy focuses on doubling revenue through CAPEX of around Rs. 100 crore, with Dahej and Roha plants as main production sites.
- No major new greenfield sites planned; further growth expected through brownfield expansions focused on specialty chemicals.
- Exports aligned with domestic demand; market-agnostic growth approach.
See what DMCC Speciality Chemicals Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company plans to raise debt of around Rs. 70 crore for its ongoing CAPEX.
- The expected debt-to-equity ratio for the CAPEX is approximately 2:1 (two-thirds debt, one-third equity).
- The interest rate on rupee borrowings is typically around 9%-10%, but with interest rate swaps, the effective rate can be reduced below 5%.
- Debt funding is expected to come mostly in the current quarter, with some already recorded post-April.
- There is no mention of any new equity fundraising planned at this time.
- No plans for additional greenfield sites or CAPEX beyond the current Rs. 100 crore investment are announced, thus limiting further fundraising needs in the immediate future.
See what DMCC Speciality Chemicals Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- The company is investing about ₹100 crore in expansion across two sites: Dahej and Roha.
- At Dahej, two multipurpose plants are being set up with a combined investment of ₹20 crore (₹10 crore each).
- The CAPEX aims to double the company's turnover, with Dahej and Roha plants expected to contribute similarly.
- Post this CAPEX phase, the company has spare land but no current plans for another greenfield site.
- The bulk chemical expansion will be mostly complete with this CAPEX, and future expansions are expected mainly in specialty projects.
- Commissioning for some projects (bulk chemicals) expected around June 2021, but specialties will take longer due to market and product approvals.
- Debt-to-equity for the CAPEX is expected at a 2:1 ratio, with borrowing costs between 9-10%, potentially lowered via interest rate swaps.
- No immediate plans for large investments beyond current CAPEX; focus remains on sulfur chemistry and expanding product lines within it.
Track DMCC Speciality Chemicals Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- Company aims to double revenue from current ~200 crore to ~400 crore once new projects fully ramp up, likely by FY24.
- Specialty chemical division targets EBITDA margins of +30% for new products; existing products maintain current margins.
- Bulk chemical products have lower margins; initial capacity ramp-up may see margin pressure but long-term margins expected similar to historical levels.
- Ongoing CAPEX of ~100 crore (Dahej and Roha plants) expected to support growth; brownfield expansions focus on specialty chemicals, no immediate new bulk chemical CAPEX planned.
- Margin impact seen due to recent raw material and freight cost spikes expected to normalize as prices adjust in contracts.
- Long-term guidance is to sustain growth within sulfur chemistry with focus on specialty and bulk chemicals and capacity utilization increasing over next 1-2 years.
- No explicit EPS forecasts given, but doubling revenues and targeted specialty margins imply improved profitability over medium term.
Order book
- Bimal Goculdas mentions good visibility for specialty products, with customers eagerly waiting for capacity to come up (Page 17).
- Several contracts exist, but specifics are not publicly disclosed due to confidentiality (Page 17).
- Specialty chemical products, particularly sulfones, are becoming substantial, with demand increasing from regions such as Japan, the U.S., and Europe (Page 14).
- Multipurpose plants require time to ramp up, including market approvals and scaling from pilot to commercial scale (Page 13).
- Overall, the company expects to have all plants commissioned and running by March 2022 with full capacity utilization depending on market conditions (Page 13).
How does DMCC Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does DMCC Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?
Compare DMCC Speciality Chemicals Ltd against every Chemicals & Petrochemicals company (Q4 FY21) on revenue, margins and earnings-call signals.
Continue your research
What DMCC Speciality Chemicals Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…